AEs leading to trial product discontinuation occurred in 51/603 (8.5%) participants in the CagriSema 2.4 mg/2.4 mg group, 40/605 (6.6%) participants in the semaglutide 2.4 mg group, 7/152 (4.6%) participants in the cagrilintide 2.4 mg group, 42/594 (7.1%) participants in the CagriSema 1 mg/1 mg group, 26/608 (4.3%) participants in the semaglutide 1 mg group, and 2/149 (1.3%) participants in the placebo group
Prof Foltynie who led the study (and is the lead investigator on the Phase III clinical trial of exenatide) added We have added to evidence that exenatide may help to prevent or treat Parkinsons disease, hopefully by affecting the course of the disease and not merely reducing symptoms, but we need to progress with our clinical trial before making any recommendations ( Source )
they act on the hypothalamus and reward circuitry of the brain
For all 8 sessions, the total is $3,200
Short answer: Noand most doctors would agree